The "Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century--A Risk Based Approach" initiative was ...
In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry ...
Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...
PE: How is AI supporting clinical trial design? Schwab: We have a hit a new era of clinical trial design. Up until 2024, ...
“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...
Vanda Pharmaceuticals announced it received a decision letter from the FDA’s Center for Drug Evaluation and Research (CDER) stating that the supplemental New Drug Application (NDA) for Hetlioz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback